Page last updated: 2024-09-05

sch 51048 and Candidiasis

sch 51048 has been researched along with Candidiasis in 2 studies

Research

Studies (2)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's1 (50.00)18.2507
2000's1 (50.00)29.6817
2010's0 (0.00)24.3611
2020's0 (0.00)2.80

Authors

AuthorsStudies
Bennett, F; Cacciapuoti, A; Ganguly, AK; Girijavallabhan, VM; Hare, RS; Jao, E; Liu, YT; Loebenberg, D; Lovey, RG; Menzel, F; Moss, E; Nomeir, A; Patel, NM; Pike, R; Pinto, P; Saksena, AK; Wang, H1
Anaissie, EJ; Dignani, MC; Karyotakis, NC1

Other Studies

2 other study(ies) available for sch 51048 and Candidiasis

ArticleYear
Hydroxylated analogues of the orally active broad spectrum antifungal, Sch 51048 (1), and the discovery of posaconazole [Sch 56592; 2 or (S,S)-5].
    Bioorganic & medicinal chemistry letters, 2006, Jan-01, Volume: 16, Issue:1

    Topics: Alcohols; Animals; Antifungal Agents; Aspergillosis; Candidiasis; Chemistry, Pharmaceutical; Dose-Response Relationship, Drug; Drug Design; Drug Evaluation, Preclinical; Haplorhini; Humans; Immunosuppressive Agents; Mice; Models, Chemical; Time Factors; Triazoles

2006
SCH 51048, a new antifungal triazole active against hematogenous Candida krusei infections in neutropenic mice.
    Antimicrobial agents and chemotherapy, 1995, Volume: 39, Issue:3

    Topics: Amphotericin B; Animals; Antifungal Agents; Candidiasis; Fluconazole; Immunosuppression Therapy; Kidney; Male; Mice; Mice, Inbred Strains; Neutropenia; Triazoles

1995